Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African population

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare the 1-year functional and anatomical outcomes of intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) in patients with myopic choroidal neovascularization (CNV).

Methods

Review of retrospectively collected data of 80 eyes in 80 patients with myopic CNV treated with standard PDT (n = 40) or IVB (1.25 mg/ 0.05 ml) (n = 40). Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) measured with optical coherence tomography (OCT) were compared between the two groups at baseline, 3, 6 and 12 months.

Results

In the IVB group, mean BCVA was +0.9 ± 0.85 logMAR at baseline. Mean BCVA was significantly better at 3 and 6 months than baseline (p = .0095 and p = .008, respectively) but not at 12 months (p = .065). In the PDT group, mean BCVA was +0.88 ± 0.45 logMAR at baseline, and improved to +0.85 ± 0.62 logMAR at 3 months and to +0.86 ± 0.44 logMAR at 6 months, which was not significantly different from baseline. Mean BCVA then decreased to +0.9 ± 0.54 logMAR at 12 months (p = .85). Mean logMAR VA was significantly better in the IVB group than in the PDT group after 3 months (p = .0043), 6 months (p = .0001) and 12 months (p = .0168). Mean CRT was significantly lower in IVB group than in PDT group at 3, 6 and 12 months (p = .008, p = .038, p = .040, respectively). Chorioretinal atrophy developed in six eyes (15%) treated with IVB and in 24 eyes (60%) treated with PDT at 12 months (p = 3.2 × 10−5).

Conclusions

Over a 12-month period, intravitreal bevacizumab seems to be superior to photodynamic therapy in controlling myopic CNV in a North-African population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241–1244

    PubMed  CAS  Google Scholar 

  2. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, Tokoro T, Mochizuki M (2003) Myopic choroidal neovascularisation: a 10-year follow-up. Ophthalmology 110:1297–1305

    Article  PubMed  Google Scholar 

  3. Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial—VIP Report No. 1. Ophthalmology 108:841–852

    Article  Google Scholar 

  4. Krebs I, Binder S, Stolba U, Glittenberg C, Brannath W, Goll A (2005) Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy. Am J Ophthalmol 140:416–425

    Article  PubMed  Google Scholar 

  5. Pece A, Isola V, Vadala M, Matranga D (2006) Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia. Retina 26:746–751

    Article  PubMed  Google Scholar 

  6. Schnurrbusch UEK, Jochmann C, Wiedemann P, Wolf S (2005) Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. Graefes Arch Clin Exp Ophthalmol 243:829–833

    Article  PubMed  Google Scholar 

  7. Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, Zack DJ, Campochiaro PA (1997) Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 151:281–291

    PubMed  CAS  Google Scholar 

  8. Study Group VIP (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial—VIP Report No. 3. Ophthalmology 110:667–673

    Article  Google Scholar 

  9. Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hara W, Yoshida T, Tokoro T, Mochizuki M (2008) Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls. Am J Ophthalmol 145(3):518–526

    Article  PubMed  CAS  Google Scholar 

  10. Ikuno Y, Nagai Y, Matsuda S, Arisawa A, Sho K, Oshita T, Takahashi K, Uchihori Y, Gomi F (2010) Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 149(1):140–146

    Article  PubMed  Google Scholar 

  11. Montero JA, Ruiz-Moreno JM (2003) Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 87:173–176

    Article  PubMed  CAS  Google Scholar 

  12. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB (2009) Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 147:84–93, e1

    Article  PubMed  CAS  Google Scholar 

  13. Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hayashi W, Yoshida T, Tokoro T, Mochizuki M (2009) Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 148:396–408

    Article  PubMed  CAS  Google Scholar 

  14. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, Tano Y (2009) Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 147:94–100, e1

    Article  PubMed  CAS  Google Scholar 

  15. Chan WM, Lai TY, Liu DT, Lam DS (2009) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 93:150–154

    Article  PubMed  Google Scholar 

  16. Ouhadj O, Bouarfa A, Akel S, Mendil L, Nebab A, Nouri MT (2010) Intravitreal ranibizumab injections for the treatment of choroidal neovascularization complicating high myopia. J Fr Ophtalmol 33:649–654, Epub 2010 Nov 2

    Article  PubMed  CAS  Google Scholar 

  17. Vadalà M, Pece A, Cipolla S, Monteleone C, Fasolino G, Casuccio A, Cillino S (2010) Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. Br J Ophthalmol Oct 8. [Epub ahead of print]

  18. Cornut PL, Poli M, Feldman A, El Chehab H, Swalduz B, Burillon C, Denis P (2010) Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month results. J Fr Ophtalmol 33:327–333

    Article  PubMed  Google Scholar 

  19. Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S (2010) Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularization. Br J Ophthalmol 94:864–870

    Article  PubMed  Google Scholar 

  20. Yoon JU, Byun YJ, Koh HJ (2010) Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 30:418–424

    Article  PubMed  Google Scholar 

  21. Gomi F, Nishida K, Oshima Y, Sakaguchi H, Sawa M, Tsujikawa M, Tano Y (2007) Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone. Am J Ophthalmol 143:507–509

    Article  PubMed  CAS  Google Scholar 

  22. Bhatnagar P, Freund KB, Spaide RF, Klancnik JM Jr, Cooney MJ, Ho I, Fine HF, Yannuzzi LA (2007) Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina 27:897–902

    Article  PubMed  Google Scholar 

  23. Prodi MB, Da Pozzo S, Ravalico G (2007) Retinal pigment epithelium changes after photodynamic therapy for choroidal neovascularization in pathological myopia. Acta Ophthalmol Scand 85:50–54

    Google Scholar 

  24. Ladas ID, Moschos MM, Rouvas AA, Karagiannis DA, Kokolakis SN (2003) Lacquer crack formation after photodynamic therapy. Eur J Ophthalmol 13:729–733

    PubMed  CAS  Google Scholar 

  25. Ohno-Matsui K, Moriyama M, Hayashi K, Mochizuki M (2006) Choroidal vein and artery occlusion following photodynamic therapy in eyes with pathologic myopia. Graefes Arch Clin Exp Ophthalmol 244:1363–1366

    Article  PubMed  Google Scholar 

  26. Lam DSC, Chan WM, Liu DTL, Fan DS, Lai WW, Chong KK (2004) Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow-up. Br J Ophthalmol 88:1315–1319

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Boulevard 9 Avril 1006 Bab Saadoun, Tunis, Tunisia

    Leila El Matri, Fedra Kort, Ahmed Chebil, Rim Bouraoui, Ahlem Merdassi & Mejda Bouladi

Authors
  1. Leila El Matri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fedra Kort
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmed Chebil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rim Bouraoui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ahlem Merdassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mejda Bouladi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leila El Matri.

Additional information

No proprietary interest, no grants and funds received, no financial support from any of the following organizations: National Institutes of Health (NIH); Wellcome Trust; Howard Hughes Medical Institute (HHMI); and other(s).

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 32 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

El Matri, L., Kort, F., Chebil, A. et al. Intravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African population. Graefes Arch Clin Exp Ophthalmol 249, 1287–1293 (2011). https://doi.org/10.1007/s00417-011-1654-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-011-1654-4

Keywords

Search

Navigation